Noncontrolling Interest (Tables)

12 Months Ended

Dec. 31, 2022

Noncontrolling Interest [Abstract]

Schedule of Noncontrolling Interest of Stockholders' Equity

The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is summarized for the periods indicated as follows:

	December 31, 2022			December 31, 2021
NCI – equity (deficit) – beginning of period	$	17,752		$	(2,369	)
Investment in Veris Health Inc.		—			6
Net loss attributable to NCI		(14,255	)		(5,779	)
Impact of subsidiary equity transactions		28			16,760
Lucid Diagnostics Inc. proceeds from Committed Equity Facility, net of deferred financing charges		1,767			—
Lucid Diagnostics Inc. issuance of common stock for settlement of APA-RDx installment payment		653			—
Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise		695			—
Lucid Diagnostics Inc. Employee Stock Purchase Plan Purchase		109			—
Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan		13,859			9,134
Stock-based compensation expense - Veris Health Inc. 2021 Equity Plan		7			—
NCI – equity (deficit) – end of period	$	20,615		$	17,752